Our Company

Diomics creates highly efficient hydrophilic materials, based on our patented Diomat™ technology, that improve the speed, sensitivity and accuracy in the capture & detection of nucleic acids, proteins and similar compounds. Learn More

Research Collaboration

Diomics has long collaborated with Professor Bruce Budowle and his lab at the University of North Texas Health Science Center. Dr. Budowle’s lab focuses on forensic and investigative genetics.

“The potential for a swab that could dissolve during extraction is monumental and has great potential in the forensic field and medical diagnostic field. The benefits could be a game changer for sample collection.”

– Dr. Bruce Budowle

Industry News

Arvinas - November 15, 2017

Genentech commits an additional $350 million to deal with protein degradation biotech Arvinas.

Arcturus - October 19, 2017

Johnson & Johnson pen deal with Arcturus to develop and sell nucleic-acid based HepB drugs.

Verogen - August 24, 2017

Illumina and Telegraph Hill Partners launch Verogen, the first sequencing company to focus solely on forensics.

⠀⠀⠀

⠀⠀⠀ ⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀ ⠀⠀⠀ ⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀ ⠀⠀⠀ ⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀ ⠀⠀⠀ ⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀ ⠀⠀⠀ ⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀ ⠀⠀⠀ ⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀ ⠀⠀⠀ ⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀ ⠀⠀⠀ ⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀ ⠀⠀⠀ ⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀⠀

Questions? Feel free to reach out to us.

We will respond to you as soon as possible.

Contact

Copyright ©2017 Diomics Corporation. All rights reserved.